Cargando…
Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials
SIMPLE SUMMARY: Mutations in the tumor suppressor p53 (p53) occur in ~50% of human cancers, the majority of which are missense mutations. Mutations in p53 not only impair the tumor suppressive function, but also confer missense mutant p53 (mutp53) with oncogenic activities independent of wild-type p...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856662/ https://www.ncbi.nlm.nih.gov/pubmed/36672377 http://dx.doi.org/10.3390/cancers15020429 |